BenchSci is partnering with Google Cloud to run its EMET platform on Google's primary infrastructure and integrate it into the Google Cloud Marketplace [1].
This collaboration aims to resolve systemic infrastructure gaps in biology by simplifying how biopharma and life-science companies access and pay for specialized research tools [1].
Under the terms of the agreement, BenchSci will combine its proprietary biological knowledge graph with Google's advanced AI models, specifically AlphaGenome and AlphaFold 3 [1], [2]. The integration is designed to streamline the workflow for enterprises already operating within the Google Cloud ecosystem [2].
By hosting the EMET platform on the Google Cloud Marketplace, the companies intend to reduce the technical friction associated with deploying complex biological data tools [1]. This move allows life-science organizations to manage their billing and access through a single provider, reducing the administrative burden on research teams [1], [2].
The partnership focuses on the intersection of large-scale cloud computing and specialized biological data [2]. By merging a knowledge graph with predictive AI models, the collaboration seeks to accelerate the way researchers identify targets and understand molecular interactions [1].
“BenchSci will combine its proprietary biological knowledge graph with Google's advanced AI models.”
This partnership represents a shift toward the 'platformization' of drug discovery. By integrating specialized biological knowledge graphs with general-purpose cloud infrastructure and protein-folding AI, Google and BenchSci are attempting to lower the barrier to entry for AI-driven research. For the biopharma industry, this means a transition from managing fragmented software stacks to using integrated cloud environments that can handle both the data storage and the complex AI computation required for modern genomics.
